What Trimetazidine Treats: Main Uses and Benefits

The primary therapeutic benefit of Trimetazidine is targeted at providing supportive relief for chronic heart conditions, specifically those characterized by symptoms related to physical discomfort. In clinical settings, this medication is used where supportive symptom management is appropriate to contribute to improved day-to-day comfort during periods of heightened symptoms. It is commonly used to help with easing the symptomatic burden associated with stable angina pectoris.

Easing Angina Discomfort and Supporting Function

This medication is applied in situations involving certain distressing symptoms, and is applied when additional symptomatic support is needed alongside other existing treatments. It is relevant for easing symptoms that interfere with daily comfort and physical function, such as reduced physical activity tolerance. The symptomatic relief may assist with maintaining functional stability during symptomatic periods. This use contributes to easing the overall symptom load, and supports general well-being during symptomatic phases, and may assist with coping more steadily with symptom fluctuations.

---

Quick Fact: Relief for Chronic Symptom Burden Trimetazidine is commonly used to help with easing chronic chest discomfort and supporting physical capacity in adult patients with stable heart conditions that present with symptomatic burden.

Trimetazidine is approved for use only in adults as an add-on therapy for the symptomatic treatment of stable angina pectoris when first-line treatments are insufficient or not tolerated. Its use is subject to specific regulatory restrictions and formal contraindications.

Populations for Whom Use is Prohibited (Contraindicated)

Contraindicated Group	Classification Basis
Parkinsonian Disorders	Parkinson disease, parkinsonian symptoms, tremors, restless leg syndrome, and other related movement disorders.
Severe Kidney Impairment	Creatinine clearance less than 30 mL/min.
Hypersensitivity	Known allergy to trimetazidine or any of the product's excipients.

Restricted or Not Recommended Populations

Restricted Group	Official Status
Pregnant Women	Avoided as a precautionary measure due to a lack of clinical data.
Breastfeeding Women	Not recommended due to unknown excretion into human milk and potential risk to the infant.
Pediatric Population	Not recommended for children and adolescents under 18 years, as safety and efficacy are not established.
Moderate Kidney Impairment	Caution is required; a dose reduction is recommended (creatinine clearance 30-60 mL/min).
Elderly Patients	Caution is advised, particularly in those over 75 years, often requiring a dose reduction due to potential for increased exposure.

Interactions with other medicines and products

The interaction profile of Trimetazidine is characterized by a general absence of major pharmacokinetic interactions. Formal drug-drug interaction studies have not identified significant metabolic pathways that would necessitate routine dose adjustments when co-administered with most medications.

Pharmacodynamic and Exposure Risks

The primary interaction-related considerations involve potential additive pharmacodynamic effects and population-specific exposure changes:

• Antihypertensive Agents: Caution is advised when Trimetazidine is co-administered with other medicinal products, particularly antihypertensive treatments. This is due to a potential additive risk for effects such as hypotension or gait instability, which may increase the risk of falls.
• Monoamine Oxidase Inhibitors (MAOIs): Some regulatory guidance advises caution or recommends against co-administration with MAOIs until non-interaction can be definitively established.

Impact of Food and Renal Function

Interaction Type	Regulatory Finding
Food	The pharmacokinetic properties are not influenced by food.
Renal Impairment	Increased exposure (higher concentration) is expected in elderly patients and those with moderate renal impairment (creatinine clearance 30–60 mL/min). This necessitates cautious use.

No specific interactions with herbal products, alcohol, or drug transport proteins (e.g., P-gp) are documented in the authoritative regulatory labeling.

Триметазидин (Trimetazidine) functions primarily by modulating myocardial energy metabolism. Its biological target is the mitochondrial long-chain 3-ketoacyl-CoA thiolase (3-KAT), an enzyme critical to the final step of beta-oxidation of fatty acids. Trimetazidine acts as a specific inhibitor of this enzyme.

Inhibition of 3-KAT partially suppresses the beta-oxidation pathway. This suppression, in turn, facilitates the shift of the cell's main energy substrate from fatty acids toward glucose oxidation. Glucose oxidation is a more oxygen-efficient process than fatty acid beta-oxidation, as it requires less oxygen to generate the same amount of adenosine triphosphate (ATP).

This metabolic shift leads to an increase in glycolytic flux and a subsequent maintenance of cellular ATP levels under conditions of limited oxygen supply. The molecular consequence is a preserved high-energy phosphate pool within the myocardial cells. System-level physiological modulation involves an enhanced efficiency of oxygen utilization at the cellular level, particularly in ischemic tissues, without directly altering hemodynamic parameters.

Trimetazidine is administered exclusively via the oral route as a long-term, supportive therapy, typically prescribed as an add-on treatment for chronic conditions. The administration protocol specifies a continuous regimen, and its proper use is structured by the specific formulation prescribed. To optimize its intake and absorption, the medicine should always be taken during meals.

---

Standard Administration and Dosing

Formulation	Standard Adult Dose	Frequency
Modified-Release (MR) 35 mg	One tablet (35 mg)	Twice daily (total 70 mg/day)
Immediate-Release (IR) 20 mg	One tablet (20 mg)	Three times a day (total 60 mg/day)

---

The Modified-Release formulation is designed to be swallowed whole; the tablets must never be chewed, crushed, or broken to ensure the integrity of the sustained release mechanism. If a dose is missed, it is generally advised to skip the missed dose entirely and resume the schedule at the next designated time, without attempting to take a double dose to compensate.

Population-Specific Use Rules

Dose adjustments are a required consideration for specific patient populations. For adults diagnosed with moderate renal impairment (Creatinine Clearance between 30 and 60 ml/min), the total daily dose is reduced. In this scenario, the recommended regimen is typically one MR 35 mg tablet taken once daily, or one IR 20 mg tablet taken twice daily. Use is not recommended for the pediatric population (under 18 years) due to insufficient established data regarding its safety and efficacy.

Триметазидин: Recent Clinical Evidence

Evidence for Symptomatic Support in Stable Angina Pectoris

Research has studied Trimetazidine in adult patients with stable angina pectoris, a condition characterized by fluctuating symptoms and functional limitations. The core evidence comes from randomized controlled trials (RCTs) and systematic reviews, where the medicine was applied in studies examining patient-reported experiences, often as an add-on to existing standard treatments. The primary focus of these investigations was on outcomes reflecting daily functioning or activity level and physical discomfort.

Research on Symptom Frequency and Nitrate Use

Studies conducted during periods of increased symptom activity monitored two key patient-reported outcomes: the weekly count of angina attacks and the consumption of rescue nitrate medications. The findings describe patterns observed in the studies where measurements related to symptom frequency and rescue medication use were different between the Trimetazidine group and the placebo group. This research helps contextualize how patients reported their experience over the defined study time intervals.

Research on Exercise Capacity and Functional Measures

Research examined outcomes reflecting daily functioning, such as total exercise duration during treadmill tests, and the time it took for certain signs of physiological strain to appear. Findings describe changes measured during the study period. This evidence contributes to understanding symptom patterns related to physiological strain in the observed populations.

Long-Term Research and Follow-up on Major Events

While the majority of trials focused on short-term symptom patterns, some large-scale prognostic studies monitored patients over much longer time intervals, lasting up to approximately four years. The evidence derived from these settings provides insight into long-term patterns, but findings were mixed. The data show patterns related to Major Adverse Cardiovascular Events (MACE) where certainty remains low. In a large event-driven trial, research describes findings where the observed outcomes were not statistically different from those reported by the placebo group.

Evidence in Specific Patient Groups

Studies have explored the use of Trimetazidine in specific patient populations, such as a subgroup of patients with stable angina who also had Type 2 Diabetes Mellitus, and those who had undergone percutaneous coronary intervention (PCI). The results apply only to the populations studied, and data for certain groups remain insufficient. Data comparing outcomes with other treatments remain limited, and subgroup findings are uncertain.

What Research Remains Uncertain About Триметазидин

The evidence base contributes to the broader evidence landscape but also highlights key areas where certainty remains low. Research is ongoing, but there is limited information for long-term outcomes related to cardiovascular events and survival. Follow-up durations were limited in many of the key short-term trials supporting symptomatic findings. Furthermore, data for the outcomes in certain populations, such as children or those with severe organ impairment, remain insufficient, and research does not determine whether an individual will respond similarly to the group patterns reported.

Key Studies & References Efficacy and safety of trimetazidine in patients with stable coronary artery disease and heart failure: The Trimetazidine in Patients with Chronic Heart Failure and Stable Coronary Artery Disease (ATPCI) randomized trial

Common questions about Триметазидин (FAQ)

Q: Can older adults safely use Триметазидин?

A: Regulatory documents describe that caution is advised when this medicine is used by older adults, especially those over 75 years of age. This is due to the potential for increased exposure to the active substance as kidney function may decrease with age. Due to this concern, regulatory documents describe that a reduction in the prescribed dose may be required for this population.

Q: Can I use Триметазидин if I have kidney impairment?

A: The official product information has specific rules regarding kidney function. Use of the medicine is strictly prohibited (contraindicated) for patients with severe kidney impairment. For those with moderate kidney impairment, the official guidance indicates that a required adjustment to the daily dosage applies.

Q: How long is a typical course of treatment with Триметазидин?

A: The medicine is described as a long-term supportive therapy if the treatment proves beneficial. Regulatory guidelines indicate that a doctor assesses the treatment benefit after three months of continuous use. If no positive response is observed after this period, treatment is typically discontinued.

Q: Are there any long-term safety concerns associated with using Триметазидин?

A: When used long-term, regulatory information notes that data concerning major cardiovascular events remains mixed. The most significant safety point involves the risk of developing movement disorders, such as tremors or gait instability. Regulatory sources confirm that these symptoms are typically reversible once treatment is definitively stopped.

Q: Can Триметазидин affect my ability to drive or operate machinery?

A: Yes, the official product information indicates that the medicine may cause effects such as dizziness and/or drowsiness. Because of this potential, the ability to drive or operate machinery may be affected. Regulatory labels recommend caution, especially when first beginning the treatment.

Q: Does Триметазидин affect heart rate or rhythm?

A: The mechanism of the medicine primarily focuses on cell metabolism and typically acts without directly altering heart rate or blood pressure. However, official safety monitoring has noted rare instances of side effects related to heart rhythm, including palpitations and a faster heartbeat (tachycardia).

Q: Can I take multivitamins or supplements while using Триметазидин?

A: Formal studies have not identified major metabolic interactions with most medications, including many common supplements. However, specific documentation detailing interactions with every single vitamin or mineral supplement is not available in the official product information. Regulatory bodies describe the importance of disclosing all products being used to a health professional.

Q: Are the side effects of Триметазидин usually mild or severe?

A: The side effect profile contains a range of possibilities classified by frequency. The most common side effects, such as headache, nausea, or dizziness, are generally considered mild. However, serious effects of unknown frequency, including movement disorders (Parkinsonian symptoms) and Hepatitis, are also noted in the official safety information.

Q: Why is it important to tell my doctor about all medications before starting Триметазидин?

A: It is important to disclose all medications due to the risk of additive effects with other treatments. Regulatory information highlights a potential cumulative risk for effects like low blood pressure (hypotension) or general unsteadiness, particularly when taken alongside high blood pressure medicines.

Q: What defines the 'unstable' conditions where Триметазидин is not suitable?

A: Regulatory documents specify that the medicine is not suitable for treating certain acute or 'unstable' heart conditions. This includes sudden, acute attacks of angina or treatment for unstable angina pectoris (a serious condition) or a heart attack (myocardial infarction). The medicine is intended only for supportive therapy of stable, chronic conditions.

Q: How quickly can I expect to notice the effects of Триметазидин?

A: While the active ingredient is absorbed relatively quickly after intake, the medicine works by causing a sustained metabolic shift in heart cells. Because of this slow-acting mechanism, the full therapeutic benefit is generally assessed by a doctor after three months of continuous use.

Q: What happens if I stop taking Триметазидин suddenly?

A: Regulatory information indicates that discontinuation occurs only under the guidance of a healthcare professional to avoid potential health consequences. If a patient develops movement disorders while using the medicine, definitive withdrawal is required. Official information states that these movement symptoms are usually reversible after the treatment is stopped.

Q: Can people with liver problems use Триметазидин?

A: Official product information has limited pharmacokinetic data regarding the use of this medicine in people with hepatic impairment (liver problems). Additionally, Hepatitis, which is inflammation of the liver, is listed as a potential side effect of unknown frequency. Official documentation stresses that the decision to use this medicine requires consultation with a doctor if a pre-existing liver condition exists.

Q: What kind of monitoring is typically required while taking Триметазидин?

A: Official guidance describes that patients should be regularly monitored, particularly older adults, to check for the occurrence or worsening of movement disorders, such as Parkinsonian symptoms. A doctor should also formally reassess the benefit of the ongoing treatment after approximately three months of continuous therapy.

Q: Why is Триметазидин sometimes prescribed for inner ear problems?

A: The medicine previously held a license for treating certain inner ear problems, such as vertigo and tinnitus (ringing in the ears). However, major regulatory bodies have since concluded that the benefits for these specific uses no longer justify the risks, and these indications have been removed from the official product information.

Q: What happens if a child accidentally takes Триметазидин?

A: If a child or anyone else accidentally takes the medicine, especially if in overdose amounts, official guidance states that immediate medical attention is required. This often involves contacting a healthcare professional or the nearest hospital emergency department.

Q: Does taking Триметазидин lead to dependency?

A: According to the available regulatory information, this medicine is not classified as an addictive substance. It is not described as being habit-forming or leading to physical dependency.

Q: Can I take Триметазидин if I have glaucoma?

A: Glaucoma is not generally listed as a contraindication for the use of this medicine. However, specific official patient information leaflets may describe that special care or consultation is necessary if a problem with increased pressure in the eyes exists, such as close-angle glaucoma.

How to Store and Dispose of Trimetazidine

Official regulatory guidelines mandate specific storage and disposal requirements to ensure the product's stability and public safety.

Storage Requirements

Trimetazidine must be stored below 25°C to maintain the stability of the active ingredient. The tablets must be kept in their original container to protect them from both light and moisture. Consistent with guidelines for all medicines, the product should be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Trimetazidine must not be disposed of via household trash or wastewater (e.g., sink or toilet). Instead, the medicine should be disposed of in accordance with local pharmaceutical waste regulations, typically by returning the product to a pharmacy or designated collection site for safe handling.